Company intelligence / Profile preview

Atonarp

Ownership: Private
Development stage: Other

Overview

Atonarp has commercialized digital molecular profiling instruments for real-time process control in semiconductor and pharmaceutical manufacturing. Its clinical diagnostics products are based on proprietary laser-based sensing technology that enables chemistry-free multiplex testing from small samples. The company’s flagship ATON360 device provides lab-quality results at the point of care without reagents or large sample volumes. In-vivo non-contact optical diagnostic platforms are under late-stage development.

Therapeutic areas: Other
Modalities: DeviceDiagnostic platform (digital molecular profiling)Optical spectroscopy platformMass spectrometry platform
Industry: Metabolite Diagnostics

Partnerships

Banner Industries (sales partnership for semiconductor applications)investors include WRVI Capital, Furukawa Electric, Japan Post Investment, Boscolo Intervest, ATI Korea

Beyond the preview

Go deeper on Atonarp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atonarp.

Explore the full profile